Logo image of PHIO

PHIO PHARMACEUTICALS CORP (PHIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PHIO - US71880W5013 - Common Stock

1.12 USD
-0.02 (-1.75%)
Last: 12/12/2025, 8:00:00 PM
1.13 USD
+0.01 (+0.89%)
After Hours: 12/12/2025, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PHIO. PHIO was compared to 531 industry peers in the Biotechnology industry. While PHIO seems to be doing ok healthwise, there are quite some concerns on its profitability. PHIO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PHIO had negative earnings in the past year.
PHIO had a negative operating cash flow in the past year.
In the past 5 years PHIO always reported negative net income.
In the past 5 years PHIO always reported negative operating cash flow.
PHIO Yearly Net Income VS EBIT VS OCF VS FCFPHIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

PHIO has a worse Return On Assets (-69.13%) than 61.77% of its industry peers.
PHIO has a Return On Equity of -80.83%. This is comparable to the rest of the industry: PHIO outperforms 51.79% of its industry peers.
Industry RankSector Rank
ROA -69.13%
ROE -80.83%
ROIC N/A
ROA(3y)-110.57%
ROA(5y)-88.07%
ROE(3y)-133.2%
ROE(5y)-105.54%
ROIC(3y)N/A
ROIC(5y)N/A
PHIO Yearly ROA, ROE, ROICPHIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

PHIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHIO Yearly Profit, Operating, Gross MarginsPHIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, PHIO has more shares outstanding
PHIO has more shares outstanding than it did 5 years ago.
PHIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PHIO Yearly Shares OutstandingPHIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
PHIO Yearly Total Debt VS Total AssetsPHIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

PHIO has an Altman-Z score of -15.53. This is a bad value and indicates that PHIO is not financially healthy and even has some risk of bankruptcy.
PHIO has a Altman-Z score of -15.53. This is amonst the worse of the industry: PHIO underperforms 81.17% of its industry peers.
There is no outstanding debt for PHIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.53
ROIC/WACCN/A
WACCN/A
PHIO Yearly LT Debt VS Equity VS FCFPHIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 6.90 indicates that PHIO has no problem at all paying its short term obligations.
PHIO has a better Current ratio (6.90) than 69.11% of its industry peers.
A Quick Ratio of 6.90 indicates that PHIO has no problem at all paying its short term obligations.
PHIO's Quick ratio of 6.90 is fine compared to the rest of the industry. PHIO outperforms 69.30% of its industry peers.
Industry RankSector Rank
Current Ratio 6.9
Quick Ratio 6.9
PHIO Yearly Current Assets VS Current LiabilitesPHIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 81.87% over the past year.
EPS 1Y (TTM)81.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.45% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y72.3%
EPS Next 2Y35.13%
EPS Next 3Y24.45%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHIO Yearly Revenue VS EstimatesPHIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2023 20M 40M 60M
PHIO Yearly EPS VS EstimatesPHIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -100K -200K -300K -400K -500K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHIO Price Earnings VS Forward Price EarningsPHIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHIO Per share dataPHIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as PHIO's earnings are expected to grow with 24.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.13%
EPS Next 3Y24.45%

More info and screens

0

5. Dividend

5.1 Amount

PHIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PHIO PHARMACEUTICALS CORP

NASDAQ:PHIO (12/12/2025, 8:00:00 PM)

After market: 1.13 +0.01 (+0.89%)

1.12

-0.02 (-1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-30 2026-03-30
Inst Owners8.75%
Inst Owner Change14.43%
Ins Owners3.68%
Ins Owner Change44.33%
Market Cap12.05M
Revenue(TTM)N/A
Net Income(TTM)-7.95M
Analysts82.86
Price Target14.28 (1175%)
Short Float %3.38%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.2%
Min EPS beat(2)-22.55%
Max EPS beat(2)4.14%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)27.66%
EPS NQ rev (3m)27.66%
EPS NY rev (1m)2.22%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.22
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)-6.48
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0
BVpS0.91
TBVpS0.91
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.13%
ROE -80.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-110.57%
ROA(5y)-88.07%
ROE(3y)-133.2%
ROE(5y)-105.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -41.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.9
Quick Ratio 6.9
Altman-Z -15.53
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)76.79%
Cap/Depr(5y)64.29%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.43%
EPS Next Y72.3%
EPS Next 2Y35.13%
EPS Next 3Y24.45%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-25.68%
EBIT Next 3Y-17.49%
EBIT Next 5YN/A
FCF growth 1Y34.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.43%
OCF growth 3YN/A
OCF growth 5YN/A

PHIO PHARMACEUTICALS CORP / PHIO FAQ

Can you provide the ChartMill fundamental rating for PHIO PHARMACEUTICALS CORP?

ChartMill assigns a fundamental rating of 2 / 10 to PHIO.


Can you provide the valuation status for PHIO PHARMACEUTICALS CORP?

ChartMill assigns a valuation rating of 1 / 10 to PHIO PHARMACEUTICALS CORP (PHIO). This can be considered as Overvalued.


What is the profitability of PHIO stock?

PHIO PHARMACEUTICALS CORP (PHIO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for PHIO stock?

The Earnings per Share (EPS) of PHIO PHARMACEUTICALS CORP (PHIO) is expected to grow by 72.3% in the next year.